Toggle light / dark theme

CAR T cell therapy could reach beyond cancer

Engineered immune cells, known as CAR T cells, have shown the world what personalized immunotherapies can do to fight blood cancers. Now, investigators have reported highly promising early results for CAR T therapy in a small set of patients with the autoimmune disease lupus. Penn Medicine CAR T pioneer Carl June, MD, and Daniel Baker, a doctoral student in Cell and Molecular Biology in the Perelman School of Medicine at the University of Pennsylvania, discuss this development in a commentary published today in Cell.

“We’ve always known that in principle, CAR T therapies could have broad applications, and it’s very encouraging to see early evidence that this promise is now being realized,” said June, who is the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Penn Medicine and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center.

T cells are among the immune system’s most powerful weapons. They can bind to, and kill, other cells they recognize as valid targets, including virus-infected cells. CAR T cells are T cells that have been redirected, through genetic engineering, to efficiently kill specifically defined .

Scientists Discover a Gene That Could Prevent Alzheimer’s Disease

Researchers at the University of Colorado Anschutz find that the overexpression of a gene improves learning and memory in Alzheimer’s.

Alzheimer’s disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer’s disease, but there are medications that can help ease the symptoms.

Understanding Senescence

Dr. Campisi has been at the forefront of studying cellular senescence for decades, revealing the mysteries of these not-exactly-dead cells and their role in many diseases of aging. In this episode, she joins her colleague Gordon to discuss the characteristics and function of senescent cells, as well as promising interventions on the horizon. Judy also describes how to get lucky in science by being prepared to see the unexpected.

Occuity lands £343k grant to develop optical diabetes screening device

DISCLOSURE: Longevity. Technology (a brand of First Longevity Limited) has been contracted by the company featured in this article to support its current funding round. Qualifying investors can find out more via the Longevity. Technology investment portal.

MedTech start-up Occuity has received a £343,000 Innovate UK Biomedical Catalyst (BMC) Award to fund the next stage of the development of its innovative AGE reader: an optical medical device that will enable non-invasive screening of diabetes in non-clinical settings such as opticians and pharmacies.

Biomedical Catalyst is the flagship Innovate UK grant funding competition for supporting UK health & life sciences SMEs. It supports the development of innovative solutions to health and healthcare challenges by providing financial support to accelerate the route to commercialisation.

Magnetic field tech captures the ‘song’ of a drug

Magnetic fields are all around us. They exist whenever there is electric current and have been used in various aspects of medicine for decades. Today, magnetic fields are used in applications including magnetic resonance imaging (MRI), bone fracture repair, wound healing and pain reduction.

Taking things a step further, US startup EMulate Therapeutics has developed a unique magnetic field technology that has been shown to replicate the effect of drugs in humans and animal models – all without the presence of chemicals. Having spun-out companies in cancer, pain management and beyond, the company is seeking partners for longevity applications of its technology.

Longevity. Technology: The concept behind EMulate’s approach is mind-boggling. The company “records” the electromagnetic signature of specific molecules and is then able to use those recordings to effect changes in cellular behaviour, without using chemicals. In its most advanced programme, EMulate’s technology has completed feasibility clinical trials for adults and children with terminal brain cancer, using a recording derived from chemotherapy drug paclitaxel. We caught up with EMulate’s CEO Chris Rivera to find out more.

Could this new ultrasound change the way cancer is treated? — BBC News

A new cancer treatment which destroys tissue non-invasively is being trialled, and, if it gains regulatory approval, it could change the way that cancers are treated in hospitals.

Histotripsy is a type of focused ultrasound which, unlike heat and radiation based treatments, is more precise – which makes it a more appealing treatment option for smaller and widespread tumours.

US based firm Histosonics is running the trial, and they are focusing their efforts on the liver – an area which is notoriously hard to treat, with low survival rates for patients.

Just 46 people worldwide have received the procedure so far, but if it proves to be safe and effective, it could be rolled out on a much bigger scale.

This film is from Click — the BBC’s weekly technology show.

Please subscribe HERE http://bit.ly/1rbfUog.

Scientists Discover a Link Between Mitochondria and Cancer

A multi-gene expression signature in tumors is associated with aggressive disease and poor patient outcomes, and it has the potential to become a genetic cancer biomarker.

The human cell’s primary source of energy, the mitochondria plays an important role in the metabolism of cancer cells. In a study recently published in PLOS ONE, researchers from throughout the world, including Dario C. Altieri, M.D., president and chief executive officer, director of the Ellen and Ronald Caplan Cancer Center, and Robert and Penny Fox Distinguished Professor at The Wistar Institute, have identified a particular gene signature indicative of mitochondrial reprogramming in tumors that is associated with a poor patient outcome.

What is the future of immunotherapy?

I want patients to know that we are making advances every day. There are treatments that can offer cures, and we plan to deliver more.

I encourage patients to talk with their physicians about innovative treatment options and consider participating in clinical trials so we can move the field forward. Together, we can unlock the promise of immunotherapy.

Padmanee Sharma, M.D., Ph.D., is professor of Genitourinary Medical Oncology and Immunology and director of scientific programs for the James P. Allison Institute.

Zapping brain cancer with long needles opens door to new treatments

University of Saskatchewan (USask) researchers have developed a new method of killing brain cancer cells while preserving the delicate tissue around it. The technique also has a remarkable side-benefit: making chemotherapy treatment of brain cancer suddenly possible.

The technique involves placing long needles through the skull and sending pulses of into a glioblastoma tumor—the pernicious variety of brain cancer that caused Tragically Hip frontman Gord Downie’s death.

“A safer and more effective cancer treatment may be clinically possible,” said Dr. Mike Moser (MD), USask College of Medicine general surgery researcher and co-author of a study published recently in the Journal of Biomechanical Engineering.